Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director · Chief Executive Officer | February 18, 2022 | February 23, 2022 |
| REVVITY, INC.RVTY · Entity 3382 | Director | May 07, 2026 | May 11, 2026 |
| Zai Lab LtdZLAB · Entity 4271 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,261.188 |
Ending reported balance
After 2022-02-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-18 · Exercise / conversion · Acquired 6,191 · Balance 70,007.188 Row 2 · 2022-02-18 · Tax withholding · Disposed 2,746 · Balance 67,261.188 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2024-02-18 | Direct | 39,119 |
Reported balance
After 2022-02-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-18 · Exercise / conversion · Disposed 6,191 · Balance 39,119 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2024-02-18 | Direct | 30,210 |
Reported balance
After 2022-02-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-18 · Other · Disposed 8,909 · Balance 30,210 F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
REVVITY, INC.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,977 |
Ending reported balance
After 2026-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-07 · Grant · Acquired 1,015 · Balance 12,712 F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Row 2 · 2026-05-07 · Grant · Acquired 1,265 · Balance 13,977 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.
Zai Lab Ltd
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 72,787 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 22,371 · Balance 72,787 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2020 Filed Mar 17, 2020 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008596 · doc4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438 Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 188 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008596 · doc4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on March 16, 2021, which is the first anniversary of the date on which the grant was made. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:20 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 3,657 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006552 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,657 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 4,847 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006552 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,657 Underlying: Common Stock · 4,847 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,150 | $333.00 | $715,950.00 |
DisclosureSEC source: 0001127602-20-006552 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,625.321 Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 4,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006552 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,775.321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 37,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005771 · form4.xml · derivative · entry 9 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,680 Underlying: Common Stock · 37,680 shares Expires 2023-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 6,762 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005771 · form4.xml · derivative · entry 8 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,048 Underlying: Common Stock · 6,762 shares Expires 2022-02-12 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 5,760 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005771 · form4.xml · derivative · entry 7 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,810 Underlying: Common Stock · 5,760 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 5,870 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005771 · form4.xml · derivative · entry 6 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,112 Underlying: Common Stock · 5,870 shares Expires 2021-02-12 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 6,234 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005771 · form4.xml · derivative · entry 5 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,982 Underlying: Common Stock · 6,234 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,555 | $331.76 | $847,646.80 |
DisclosureSEC source: 0001127602-20-005771 · form4.xml · nonDerivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,928.321 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 5,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005771 · form4.xml · nonDerivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,483.321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,340 | $331.76 | $776,318.40 |
DisclosureSEC source: 0001127602-20-005771 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,723.321 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 6,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005771 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,063.321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:20 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,772 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017441 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,772 shares Expires 2019-05-02 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,480 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017441 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,772 Underlying: Common Stock · 1,480 shares Expires 2019-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 658 | $230.52 | $151,682.16 |
DisclosureSEC source: 0001127602-19-017441 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,829.321 Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017441 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,487.321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:30 UTC | BIOGEN INC. BIIB · Entity 1675 | PurchaseCommon Stock | 4,351 | $231.48 | $1,007,169.48 |
DisclosureSEC source: 0001127602-19-016956 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,007.321 F1 · price: This represents the weighted average price for shares purchased at a range between $231.47 (low) and $232.06 (high). F2 · price: Full information regarding the number of shares purchased at each separate price will be provided to the SEC staff, the issuer or any security holder of the issuer, upon their request. F3 · balance_after: Includes 82.051 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2019. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 3,229 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007262 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,504 Underlying: Common Stock · 3,229 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 5,269 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007262 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,733 Underlying: Common Stock · 5,269 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,340 | $332.87 | $778,915.80 |
DisclosureSEC source: 0001127602-19-007262 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,574.27 Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 5,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007262 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,914.27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 37,570 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006101 · form4.xml · derivative · entry 5 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,570 Underlying: Common Stock · 37,570 shares Expires 2022-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 5,205 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006101 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,216 Underlying: Common Stock · 5,205 shares Expires 2021-02-12 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 6,899 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006101 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,421 Underlying: Common Stock · 6,899 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,622 | $319.43 | $837,545.46 |
DisclosureSEC source: 0001127602-19-006101 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,645.27 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 6,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006101 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,267.27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2018 Filed May 4, 2018 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,557 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016415 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,252 Underlying: Common Stock · 1,557 shares Expires 2019-05-02 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F3 · derivative.underlying_shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. Read SEC document |
| May 02, 2018 Filed May 4, 2018 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,687 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016415 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,809 Underlying: Common Stock · 1,687 shares Expires 2019-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| May 02, 2018 Filed May 4, 2018 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 750 | $274.13 | $205,597.50 |
DisclosureSEC source: 0001127602-18-016415 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,368.27 Read SEC document |
| May 02, 2018 Filed May 4, 2018 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016415 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,118.27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 74.812 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2018. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:27 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007215 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,002 Underlying: Common Stock · 3,144 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 5,354 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007215 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,146 Underlying: Common Stock · 5,354 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,877 | $299.38 | $561,936.26 |
DisclosureSEC source: 0001127602-18-007215 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,356.458 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 5,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007215 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,233.458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:38 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 36,320 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006182 · form4.xml · derivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,320 Underlying: Common Stock · 36,320 shares Expires 2021-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | PurchaseCommon Stock | 780 | $320.55 | $250,029.00 |
DisclosureSEC source: 0001127602-18-000128 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,879.458 F1 · kind: Purchase pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| May 02, 2017 Filed May 4, 2017 20:16 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,508 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016857 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,496 Underlying: Common Stock · 1,508 shares Expires 2019-05-02 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| May 02, 2017 Filed May 4, 2017 20:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,736 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016857 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,004 Underlying: Common Stock · 1,736 shares Expires 2019-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This award was previously reported as covering 9,520 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F1 · derivative.underlying_shares: This award was previously reported as covering 9,520 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017. F1 · balance_after: This award was previously reported as covering 9,520 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017. Read SEC document |
| May 02, 2017 Filed May 4, 2017 20:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 564 | $271.34 | $153,035.76 |
DisclosureSEC source: 0001127602-17-016857 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,099.458 Read SEC document |
| May 02, 2017 Filed May 4, 2017 20:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016857 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,663.458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2017 Filed May 2, 2017 20:18 UTC | BIOGEN INC. BIIB · Entity 1675 | PurchaseCommon Stock | 1,402 | $271.35 | $380,432.70 |
DisclosureSEC source: 0001127602-17-016342 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,927.458 F1 · kind: Purchase pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 91.527 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2017. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | PurchaseCommon Stock | 1,333 | $285.39 | $380,424.87 |
DisclosureSEC source: 0001127602-17-009254 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433.931 F1 · kind: Purchase pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 100.9310 shares acquired under the Biogen Inc. employee stock purchase plan on 09/30/16 and 12/30/16. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:30 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 25,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007116 · form4.xml · derivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.